Results 251 to 260 of about 37,800,474 (344)

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

Urea-functionalized HKUST-1 metal-organic framework for high-performance lead adsorption. [PDF]

open access: yesRSC Adv
Hashad NM   +9 more
europepmc   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

open access: yesMolecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller   +17 more
wiley   +1 more source

Design of high-performance sustainable aluminum alloy series for laser additive manufacturing. [PDF]

open access: yesNat Commun
Takata N   +9 more
europepmc   +1 more source

Algorithm-Guided Experimentation for Optimization of High-Performance Perovskite Solar Cells. [PDF]

open access: yesACS Energy Lett
Oh D   +4 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

HIGH-PERFORMANCE COMPUTING MEETS HIGH-PERFORMANCE MEDICINE

Biocomputing 2023, 2022
The following sections are included: Introduction, Background, and Motivation, Workshop Presenters, References.
Anurag, Verma   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy